Finally, these data raise the exciting possibility that HMGB1 antagonists such as glycyrrhizin and several anti-inflammatory and neuroprotective endogenous mediators such as endocannabinoids might prevent both headaches and unwanted inflammatory reactions to functional perturbations in nondegenerating CNS disorders [87–89]. This evidence concerns the gene HMGB1 and central nervous system disorder.